Add time:08/16/2019         Source:sciencedirect.com

Objective To determine the structure (disease) modifying effect of a glycosaminoglycan polypeptide association complex (GP-C; Rumalon®) in patients with knee and hip osteoarthritis (OA).Methods Double-blind, randomized, placebo-controlled five-year study. Primary assessment criterion was change in radiographic joint space width between baseline and follow-up at 5 years. Secondary outcome criteria included Lequesne algofunctional index (LAI), pain on passive motion and consumption of non-steroidal antiinflammatory drugs (NSAIDs). The patients received 10 courses of injections of placebo or GP-C 2 ml intramuscularly in 5 years (two courses each year). Each course included 15 injections administered twice weekly.Results There were 277 patients with knee OA and 117 patients with hip OA. Control and GP-C treated groups were comparable as to sex, age, duration of disease, body weight, X-ray stage and value of LAI at the baseline. Knee joint space at 5 years decreased 0.37±0.08 (mean±standard deviation) mm for GP-C and 0.42±0.08 mm for placebo groups (P=0.68). Hip joint space at 5 years decreased 0.21±0.08 mm for GP-C and 0.22±0.08 mm for placebo groups (P=0.53). In a subset of patients with hip OA, Kellgren–Lawrence≥2 and JSW≥1 mm, there was a trend in favor of GPC for lower joint space narrowing in 5 years (P=0.11). In addition, there were no statistical differences between the treatment groups in LAI, pain on passive motion and consumption of NSAIDs. Side-effects after GP-C (14.5%) were rare, mild and not more frequent than in the placebo group (15%).Conclusion We were not able to demonstrate a structure modifying effect of GP-C in OA of the hip or knee. Radiographic progression of OA in both knee and hip OA was lower than expected in both study groups.

We also recommend Trading Suppliers and Manufacturers of Rumalon (cas 11035-03-3). Pls Click Website Link as below: cas 11035-03-3 suppliers